Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 5;8(3):28.
doi: 10.3390/jpm8030028.

A Metabolomics Approach to Pharmacotherapy Personalization

Elena E Balashova  1 , Dmitry L Maslov  2 , Petr G Lokhov  3
Affiliations
Review

A Metabolomics Approach to Pharmacotherapy Personalization

Elena E Balashova et al. J Pers Med. .

Abstract

The optimization of drug therapy according to the personal characteristics of patients is a perspective direction in modern medicine. One of the possible ways to achieve such personalization is through the application of "omics" technologies, including current, promising metabolomics methods. This review demonstrates that the analysis of pre-dose metabolite biofluid profiles allows clinicians to predict the effectiveness of a selected drug treatment for a given individual. In the review, it is also shown that the monitoring of post-dose metabolite profiles could allow clinicians to evaluate drug efficiency, the reaction of the host to the treatment, and the outcome of the therapy. A comparative description of pharmacotherapy personalization (pharmacogenomics, pharmacoproteomics, and therapeutic drug monitoring) and personalization based on the analysis of metabolite profiles for biofluids (pharmacometabolomics) is also provided.

Keywords: mass spectrometry; metabolomics; personalized medicine; pharmacogenomics; pharmacometabolomics; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
A schematic of the traditional (arrow A) and individual (arrow B) approaches to medical treatment.
Figure 2
Figure 2
A biological system represented as a complex interaction of the genome, transcriptome, proteome, and metabolome.
Figure 3
Figure 3
Factors that determine individual drug responses.
Figure 4
Figure 4
Mass spectrum of human blood plasma metabolites acquired by DIMS in the positive mode of micrOTOF-Q (BrukerDaltonik Ltd., Billerica, MA, USA). The labels indicate the different metabolite groups detected. The upper panel is a representative image of biodegradation (in this case, of vitamin A). The m/z values for mass peaks of vitamin A and its derivates (adducts, fragments, and multi-ions) are also presented.
See this image and copyright information in PMC

References

    1. Aspinall M.G., Hamermesh R.G. Realizing the promise of personalized medicine. Harv. Bus. Rev. 2007;85:108–117. - PubMed
    1. Piquette-Miller M., Grant D.M. The art and science of personalized medicine. Clin. Pharmacol. Ther. 2007;81:311–315. doi: 10.1038/sj.clpt.6100130. - DOI - PubMed
    1. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200. - DOI - PubMed
    1. Patidar D., Rajput M.S., Nirmal N.P., Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip. Toxicol. 2013;6:41–46. doi: 10.2478/intox-2013-0008. - DOI - PMC - PubMed
    1. Alomar M.J. Factors affecting the development of adverse drug reactions. Saudi Pharm. J. 2014;22:83–94. doi: 10.1016/j.jsps.2013.02.003. - DOI - PMC - PubMed

LinkOut - more resources